SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals Ltd has published its audited standalone financial results for Q4 and the financial year ended 31 March 2026 in newspapers (Financial Express and Andhra Prabha). For the quarter, total income was Rs 1,085.73 Lakhs with net profit after tax of Rs 7.50 Lakhs. For the full year, total income stood at Rs 3,906.20 Lakhs with net profit after tax of Rs 104.96 Lakhs. The Board of Directors has recommended a final dividend of Rs 1 per equity share for FY2026, subject to shareholder approval at the AGM. The results were reviewed by the Audit Committee and approved by the Board on 23 May 2026.
The modest EPS of Rs 1.02 for FY2026 and low Q4 profit of Rs 7.50 Lakhs suggest weaker performance in the later quarter. The dividend recommendation provides some return signal to shareholders.